Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57432 | 1.00 | CA2 (0.50) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL83699 | 1.00 | CA2 (0.50) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL464290 | 0.93 | CTSK (0.45) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL30673406 | 0.86 | CA1 (0.46) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL206502 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL873787 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL873398 | 0.86 | CA1 (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL23722683 | 0.84 | CA1 (0.43) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL3805811 | 0.84 | CTSK (0.44) | CA2CA1CA7CTSKCTSS | |
| SCHEMBL21746358 | 0.84 | CA1 (0.43) | CA2CA1CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 810 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017221-A1 | SYNTHESIS METHOD FOR α-AZIDO KETONE CONTAINING TERTIARY STEREOCENTER | 常州大学 | 2024-01-25 | — | — | WO | claimed |
| CN-115108937-B | Synthesis method of alpha-azido ketone containing three-level stereo center | 常州大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115611881-A | Method for synthesizing novel VHL ligand 4-F-VH032 | 复旦大学 | 2023-01-17 | — | — | CN | claimed |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125421-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109672-A1 | SARS-COV-2 MPRO INHIBITORS AND USES THEREOF | NXERA PHARMA UK LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1047665-A1 | MATRIX METALLOPROTEASE INHIBITORS | Pfizer Limited (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999035124-A1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| US-5338726-A | Hypotensive agents, antiulcer agents | ABBOTT LABORATORIES (US) | 1994-08-16 | — | — | US | disclosed |
| US-5304549-A | Control or prevention of degenerative joint diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-04-19 | — | — | US | disclosed |
| WO-1993001166-A1 | 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES | SANDOZ LTD. (CH) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992013545-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | CA2 634/4885CA1 1860/4885CA7 825/4885 |
| US-20260109672-A1 | SARS-COV-2 MPRO INHIBITORS AND USES THEREOF | ACE2, ACE, TMPRSS2 | CA2 351/4885CA1 2298/4885CA7 302/4885 |
| US-20260125421-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, GTF3C3 | CA2 934/4885CA1 1307/4885CA7 338/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | CA2 2413/4885CA1 2045/4885CA7 3020/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | CA2 3749/4885CA1 3147/4885CA7 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.